These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2906875)

  • 1. Penbutolol: pharmacokinetics, effect on exercise tachycardia, and in vitro inhibition of radioligand binding.
    Brockmeier D; Hajdù P; Henke W; Mutschler E; Palm D; Rupp W; Spahn H; Verho MT; Wellstein A
    Eur J Clin Pharmacol; 1988; 35(6):613-23. PubMed ID: 2906875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Penbutolol: beta-adrenoceptor interaction and the time course of plasma concentrations explain its prolonged duration of action in man.
    Wellstein A; Palm D
    Eur J Clin Pharmacol; 1985; 29(3):293-300. PubMed ID: 3000796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor binding of propranolol is the missing link between plasma concentration kinetics and the effect-time course in man.
    Wellstein A; Palm D; Pitschner HF; Belz GG
    Eur J Clin Pharmacol; 1985; 29(2):131-47. PubMed ID: 3000793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative beta-adrenoceptor blocking effects and pharmacokinetics of penbutolol and propranolol in man.
    Giudicelli JF; Richer C; Chauvin M; Idrissi N; Berdeaux A
    Br J Clin Pharmacol; 1977 Apr; 4(2):135-40. PubMed ID: 16632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic and pharmacokinetic study of oral and intravenous penbutolol.
    Vedin JA; Wilhelmsson C; Maass L; Peterson LE
    Eur J Clin Pharmacol; 1983; 25(4):529-34. PubMed ID: 6653649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Penbutolol and propranolol: a comparison of their effects on antipyrine clearance in man.
    Bax ND; Jones RW; Lennard MS; Tucker GT; Woods HF
    Br J Clin Pharmacol; 1985 May; 19(5):593-6. PubMed ID: 4005101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single and divided doses of penbutolol.
    Müller FO; Hundt HK; Bromley PA; Torres J; Vanderbeke O
    Clin Pharmacol Ther; 1979 May; 25(5 Pt 1):528-35. PubMed ID: 436357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Penbutolol Pharmacokinetics: the influence of concomitant administration of cimetidine.
    Spahn H; Kirch W; Hajdu P; Mutschler E; Ohnhaus EE
    Eur J Clin Pharmacol; 1986; 29(5):555-60. PubMed ID: 3956561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ethnic differences in beta-1-adrenoceptor sensitivity.
    Venter CP; Joubert PH
    S Afr Med J; 1982 Nov; 62(23):849-50. PubMed ID: 6755764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Extent of beta-blocking action of S- and R-penbutolol during exercise testing (author's transl)].
    Kober G; Schulz W; Hermann HJ; Kaltenbach M
    Z Kardiol; 1982 Apr; 71(4):289-94. PubMed ID: 6283753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haemodynamic dose-response effects of i.v. penbutolol in angina pectoris.
    Silke B; Verma SP; Hussain M; Nelson GI; Okoli RC; Taylor SH
    Br J Clin Pharmacol; 1983 Nov; 16(5):529-35. PubMed ID: 6315039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of conventional and controlled-release formulations of metipranolol in man.
    Lapka R; Sechser T; Rejholec V; Peterková M; Votavová M
    Eur J Clin Pharmacol; 1990; 38(3):243-7. PubMed ID: 1971217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Affinity of (+/-)-pindolol, (-)-penbutolol, and (-)-tertatolol for pre- and postsynaptic serotonin 5-HT(1A) receptors in human and rat brain.
    Castro ME; Harrison PJ; Pazos A; Sharp T
    J Neurochem; 2000 Aug; 75(2):755-62. PubMed ID: 10899952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Penbutolol: a new beta-adrenergic blocking agent.
    Schlanz KD; Thomas RL
    DICP; 1990 Apr; 24(4):403-8. PubMed ID: 2183495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of penbutolol on plasma atrial natriuretic peptide and antidiuretic hormone levels before and after exercise: a double-blind comparison against placebo.
    Verho M; Färber G; Kirsten R; Nelson K
    Pharmatherapeutica; 1989; 5(5):320-8. PubMed ID: 2526341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of penbutolol and its metabolites in renal insufficiency.
    Bernard N; Cuisinaud G; Pozet N; Zech PY; Sassard J
    Eur J Clin Pharmacol; 1985; 29(2):215-9. PubMed ID: 4076321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind trial of penbutolol: a new beta-receptor blocking agent in the treatment of angina pectoris.
    Agarwal AK; Ahuja RC; Chandra M; Gupta NN; Hasan M
    J Int Med Res; 1976; 4(6):410-7. PubMed ID: 17557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics of piretanide tablets, penbutolol tablets and the fixed combination of both drugs in healthy male subjects after a single oral dose.
    Müller F; Meyer B; Grigoleit HG
    Int J Clin Pharmacol Res; 1987; 7(6):469-75. PubMed ID: 3440637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of penbutolol in healthy and cancer subjects: role of altered protein binding.
    Aguirre C; Trocóniz IF; Valdivieso A; Jiménez RM; González JP; Calvo R; Rodríguez-Sasiaín JM
    Res Commun Mol Pathol Pharmacol; 1996 Apr; 92(1):53-72. PubMed ID: 8733828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The excretion of renal enzymes during rest and exercise: a double-blind comparison between placebo and penbutolol.
    Verho M; Färber G; Heinen B; Grötsch H
    Int J Clin Pharmacol Res; 1987; 7(1):27-32. PubMed ID: 2884191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.